People: Pacific Biosciences of California Inc (PACB.OQ)
PACB.OQ on NASDAQ Stock Exchange Global Select Market
2.67USD
1 Aug 2013
2.67USD
1 Aug 2013
Price Change (% chg)
$0.08 (+3.09%)
$0.08 (+3.09%)
Prev Close
$2.59
$2.59
Open
$2.64
$2.64
Day's High
$2.67
$2.67
Day's Low
$2.54
$2.54
Volume
28,380
28,380
Avg. Vol
88,908
88,908
52-wk High
$3.25
$3.25
52-wk Low
$1.09
$1.09
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Michael Hunkapiller |
64 | 2012 | Chairman of the Board, President, Chief Executive Officer |
Susan Barnes |
58 | 2010 | Chief Financial Officer, Executive Vice President |
Kevin Corcoran |
53 | 2012 | Senior Vice President - Market Development |
Michael Phillips |
61 | 2010 | Senior Vice President - Research and Development |
William Ericson |
54 | 2010 | Lead Independent Director |
John Milligan |
52 | 2013 | Director |
David Botstein |
70 | 2012 | Independent Director |
Brook Byers |
67 | 2004 | Independent Director |
Randy Livingston |
59 | 2009 | Independent Director |
Marshall Mohr |
57 | 2012 | Independent Director |
Lucy Shapiro |
72 | 2012 | Independent Director |
Biographies
| Name | Description |
|---|---|
Michael Hunkapiller |
Dr. Michael W. Hunkapiller, Ph.D., is Chairman of the Board, President, Chief Executive Officer of Pacific Biosciences of California, Inc. He became President and Chief Executive Officer of Pacific Biosciences in 2012. He is Chairman of the Board of Directors, and has served on the Board of Directors since 2005. Since November 2004, Dr. Hunkapiller has been a General Partner at Alloy Ventures, or Alloy, a venture capital firm. Prior to Alloy, Dr. Hunkapiller spent 21 years at Applied Biosystems (now Life Technologies). At Applied Biosystems, he held various positions, most recently serving as president and general manager. Dr. Hunkapiller holds a PhD in Chemical Biology from the California Institute of Technology and a B.S. in Chemistry from Oklahoma Baptist University. |
Susan Barnes |
Ms. Susan K. Barnes is Chief Financial Officer, Executive Vice President of Pacific Biosciences of California Inc., since December 2010. She joined the company in February 2010 as Senior Vice President and Chief Financial Officer and was promoted to Executive Vice President and Chief Financial Officer in December 2010. From 1997 to 2005, she was senior vice president, finance and chief financial officer of Intuitive Surgical, Inc. Ms. Barnes served on several boards of directors of public and private companies, including Northstar Neuroscience, Inc. from February 2006 to December 2009, where she also served as Audit Committee chair, and RAE Systems from September 2004 to May 2006, where she served as chair of the Audit Committee. Ms. Barnes holds an A.B. from Bryn Mawr College and an M.B.A. from the Wharton School, University of Pennsylvania. |
Kevin Corcoran |
Mr. Kevin Corcoran is Senior Vice President - Market Development of Pacific Biosciences of California Inc. He joined Pacific Biosciences in 2007 as Vice President of software and informatics development. In March 2011 Mr. Corcoran was promoted to Senior Vice President and was responsible for all systems related development for the PacBio RS SMRT Sequencing System, and in March 2012, he became Senior Vice President of Market Development and is responsible for overall management of developing and increasing market opportunities for current and future products. Mr. Corcoran served as President and CEO of Lynx Therapeutics from 2002 to 2004 where he was responsible for the development and commercialization of a massively parallel short read sequencing technology. While at Lynx, Mr. Corcoran jointly acquired with Solexa management the DNA cluster amplification technology, which is now a key component of Illumina’s sequencing platforms. From 2004 to 2007 Mr. Corcoran served as Vice President and General Manager of Applied Biosystems DNA sequencing business. While at ABI, Mr. Corcoran managed the teams responsible for the commercial development and deployment of SOLiD. Mr. Corcoran holds a B.S. in Computer Science from California State University, Hayward. |
Michael Phillips |
Mr. Michael Phillips is Senior Vice President - Research and Development of Pacific Biosciences of California Inc. He joined Pacific Biosciences in April 2005 as Vice President of Product Development and since February 2010 has served as Senior Vice President of Research and Development. Prior to joining the company, Mr. Phillips held various management roles at Applied Biosystems spanning research and development, test, manufacturing operations and service support from 1986 to April 2005. His most recent position at Applied Biosystems was Senior Director, Research and Development. Mr. Phillips earned a B.S. degree in Bacteriology from the University of California, Davis. |
William Ericson |
Mr. William Ericson serves as Lead Independent Director of Pacific Biosciences of California Inc. Mr. Ericson has been a member of Board of Directors since 2004 and Lead Independent Director since 2010. Mr. Ericson is a Managing Partner at Mohr Davidow Ventures, or MDV, a venture capital firm. He joined MDV in 2000 after more than a decade of working closely with entrepreneurs to start and build innovative businesses in the role of lawyer, board member, entrepreneur and investor, and has led MDV’s focus on personalized medicine investing since 2003. Mr. Ericson holds a B.S.F.S. from Georgetown University School of Foreign Service and a J.D. from Northwestern University School of Law. |
John Milligan |
Dr. John F. Milligan, Ph.D., has been appointed as Director of Pacific Biosciences of California, Inc., effective July 17, 2013. Dr. Milligan is currently the President and Chief Operating Officer of Gilead Sciences, Inc., a publicly-traded biopharmaceutical company, where he has been since 1990. He is also currently serving on the board of Biotechnology Industry Organization, and is a trustee of Ohio Wesleyan University. Dr. Milligan holds a B.A. in Chemistry from Ohio Wesleyan University and a Ph.D. in Biochemistry from the University of Illinois. He was also an American Cancer Society postdoctoral fellow at the University of California at San Francisco. |
David Botstein |
Dr. David Botstein, Ph.D., is Independent Director of Pacific Biosciences of California, Inc. Dr. Botstein is Director of the Lewis-Sigler Institute for Integrative Genomics and Anthony B. Evnin Professor of Genomics at Princeton University, where he has served since 2003. From 1990 to 2003 he was Chairman of the Department of Genetics at Stanford University. Previously, he was Vice President for Science at Genentech, and today serves on Genentech’s Scientific Resource Board. He is a member of the National Academy of Sciences and the Institute of Medicine, and has received numerous awards for his achievements in science. Dr. Botstein has made fundamental contributions to modern genetics, including the discovery of many yeast and bacterial genes and the establishment of key techniques that are commonly used today. In 1980, Dr. Botstein and three colleagues proposed a method for mapping genes that laid the groundwork for the Human Genome Project. Dr. Botstein holds a PhD in Human Genetics from the University of Michigan and an A.B. in Biochemical Sciences from Harvard. |
Brook Byers |
Mr. Brook H. Byers serves as Independent Director of Pacific Biosciences of California Inc., since 2004. Mr. Byers has been a venture capital investor since 1972 and is a Managing Partner of Kleiner Perkins Caufield & Byers. He has been closely involved with more than 50 new technology-based ventures, many of which have already become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led Kleiner Perkins Caufield & Byers to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. Mr. Byers served on the board of directors of Genomic Health, Inc. from 2001 to 2011. Mr. Byers holds a B.S. degree in Electrical Engineering from the Georgia Institute of Technology and an M.B.A from Stanford University. |
Randy Livingston |
Mr. Randy Livingston serve as Independent Director of Pacific Biosciences of California Inc., since 2009. He has served as Vice President for Business Affairs and Chief Financial Officer of Stanford University since March 2001. Before joining Stanford, Mr. Livingston served as the executive vice president, chief financial officer and a director of OpenTV Corp. from 1999 to 2001. Before joining OpenTV in 1999, Mr. Livingston served as a consultant and part-time chief financial officer for Silicon Valley technology companies with such diverse specialties as genomics, Internet commerce, medical devices, chemical synthesis and enterprise software. Previously, he was director of corporate development at Apple Computer and chief financial officer for Taligent. Mr. Livingston currently serves as a director of Genomic Health, Inc. and eHealth, Inc. Mr. Livingston holds a B.S. in Mechanical Engineering and an M.B.A. from Stanford University. |
Marshall Mohr |
Mr. Marshall L. Mohr serves as Independent Director of Pacific Biosciences of California, Inc., since January 18, 2012. Since March 2006, he has been Senior Vice President and Chief Financial Officer of Intuitive Surgical, Inc., a provider of surgical robotics. Prior to joining Intuitive Surgical, Mr. Mohr served as Vice President and Chief Financial Officer of Adaptec, Inc. Before 2003, Mr. Mohr was an audit partner with PricewaterhouseCoopers LLP where he was most recently the managing partner of the firm’s West Region Technology Industry Group and led its Silicon Valley accounting and audit advisory practice. Since 2005, Mr. Mohr has been a member of the board of directors and chairman of the audit committee of Plantronics, Inc., a provider of lightweight communications headsets and telephone headset systems, and also served as a member of the board of directors and chairman of the audit committee of Atheros Communications, Inc., a developer of semiconductor system solutions for wireless communications products, from November 2003 to May 2011 when Atheros was sold to Qualcomm, Inc. Mr. Mohr holds a Bachelor of Business Administration in Accounting and Finance from Western Michigan University. |
Lucy Shapiro |
Dr. Lucy Shapiro, Ph.D., is Independent Director of Pacific Biosciences of California, Inc. Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University’s School of Medicine, where she has been as a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc. In 1989, Dr. Shapiro founded Stanford University’s Department of Developmental Biology, and served as its Chairman from 1989 to 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University. She received a B.A. from Brooklyn College and a PhD in Molecular Biology from the Albert Einstein College of Medicine. Dr. Shapiro has received numerous awards and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006. Dr. Shapiro was also a director of Gen-Probe, Inc. from 2008 to 2012. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Michael Hunkapiller |
2,177,000 |
Susan Barnes |
1,029,300 |
Kevin Corcoran |
1,109,520 |
Michael Phillips |
825,804 |
William Ericson |
-- |
John Milligan |
-- |
David Botstein |
-- |
Brook Byers |
-- |
Randy Livingston |
-- |
Marshall Mohr |
-- |
Lucy Shapiro |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Michael Hunkapiller |
0 | 0 |
Susan Barnes |
47,058 | 199,526 |
Kevin Corcoran |
0 | 0 |
Michael Phillips |
0 | 0 |
William Ericson |
0 | 0 |
John Milligan |
0 | 0 |
David Botstein |
0 | 0 |
Brook Byers |
0 | 0 |
Randy Livingston |
0 | 0 |
Marshall Mohr |
0 | 0 |
Lucy Shapiro |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
HUNKAPILLER MICHAEL W |
56,700 | $1.75 |
HUNKAPILLER MICHAEL W |
97,400 | $1.76 |
HUNKAPILLER MICHAEL W |
97,400 | $1.74 |
HUNKAPILLER MICHAEL W |
97,400 | $1.68 |
HUNKAPILLER MICHAEL W |
47,400 | $1.55 |
HUNKAPILLER MICHAEL W |
97,400 | $1.49 |
HUNKAPILLER MICHAEL W |
50,000 | $1.45 |
HUNKAPILLER MICHAEL W |
39,000 | $1.32 |
HUNKAPILLER MICHAEL W |
65,600 | $1.27 |
HUNKAPILLER MICHAEL W |
89,400 | $1.26 |
HUNKAPILLER MICHAEL W |
100,000 | $1.21 |
HUNKAPILLER MICHAEL W |
150,000 | $1.12 |
HUNKAPILLER MICHAEL W |
12,300 | $1.13 |
HUNKAPILLER MICHAEL W |
347,500 | $1.75 |
HUNKAPILLER MICHAEL W |
52,500 | $1.75 |
MARTIN HUGH |
108,009 | $0.00 |
MARTIN HUGH |
16,762 | $1.96 |
MARTIN HUGH |
52,412 | $0.70 |
HUNKAPILLER MICHAEL W |
30,000 | $5.68 |
SIEGEL SUSAN E |
65,000 | $0.70 |
HUNKAPILLER MICHAEL W |
70,000 | $5.81 |

